Literature DB >> 11838626

Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.

Alex Hofer1, Georg Kemmler, Ursula Eder, Michaela Honeder, Martina Hummer, W Wolfgang Fleischhacker.   

Abstract

BACKGROUND: A cross-sectional study was conducted in patients with schizophrenia who regularly attended an outpatient clinic to examine the impact of psychopathology, side effects, and sociodemographic factors on attitudes toward antipsychotics.
METHOD: Sixty patients with a schizophrenic disorder according to ICD-10 criteria who had a duration of illness over 1 year and whose discharge from an inpatient unit had been at least 6 weeks earlier were investigated. Apart from the registration of demographic data, various rating scales were used: the Positive and Negative Syndrome Scale, the St. Hans Rating Scale for Extrapyramidal Syndromes, the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale, and the Drug Attitude Inventory (DAI).
RESULTS: Generally, the aspects describing a positive attitude toward antipsychotics on the DAI received a higher degree of assent than those characterizing a negative drug attitude. However, employment status correlated with a poorer global medication attitude on the DAI, and positive symptoms and sedation correlated with greater negative feelings on the DAI subjective negative feelings subscale.
CONCLUSION: Our results suggest that special attention should be paid to patients who experience positive symptoms or sedation and to those with relative absence of symptoms, who are therefore tempted to stop taking medication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11838626     DOI: 10.4088/jcp.v63n0110

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  20 in total

1.  Social interaction and drug attitude effectiveness in patients with schizophrenia.

Authors:  Jui-Kang Tsai; Wen-Kuo Lin; For-Wey Lung
Journal:  Psychiatr Q       Date:  2011-12

2.  Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.

Authors:  Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer
Journal:  BMC Psychiatry       Date:  2018-06-28       Impact factor: 3.630

3.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

4.  Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR).

Authors:  Alessandra Barraco; Andrea Rossi; Giuseppe Nicolò
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

5.  Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

Authors:  Raisa Andrezina; Richard C Josiassen; Ronald N Marcus; Dan A Oren; George Manos; Elyse Stock; William H Carson; Taro Iwamoto
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

6.  Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.

Authors:  Alex Hofer; Maria A Rettenbacher; Christian G Widschwendter; Georg Kemmler; Martina Hummer; W Wolfgang Fleischhacker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-29       Impact factor: 5.270

7.  Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Authors:  Christopher Carswell; Amanda Wheeler; Jane Vanderpyl; Elizabeth Robinson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 8.  Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.

Authors:  Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models.

Authors:  Alessandro Rossi; Roberta Pacifico; Paolo Stratta
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 10.  Patient and family attitudes toward schizophrenia treatment.

Authors:  Farzin Irani; Mary Dankert; Steven J Siegel
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.